What the FDA labels say about taking them together
Everolimus and trandolapril
Trandolapril's FDA label of October 31, 2025 names everolimus in its drug interactions section; everolimus's label does not name trandolapril itself but warns about its class (ACE inhibitors). The trandolapril label: “Mammalian Target of Rapamycin (mTOR) Inhibitors Patients taking concomitant mTOR inhibitor therapy may be at increased risk for angioedema.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the trandolapril FDA label on DailyMed (effective October 31, 2025, Lupin Pharmaceuticals, Inc.).
What does the everolimus label say about trandolapril?
Everolimus's label does not name trandolapril itself; it warns about its class (ACE inhibitors):
Everolimus label, drug interactionsUse of Angiotensin Converting Enzyme (ACE) Inhibitors Patients taking concomitant ACE inhibitors with AFINITOR/AFINITOR DISPERZ may be at increased risk for angioedema.
Everolimus label, drug interactionsAvoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)].
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the trandolapril label say about everolimus?
Trandolapril label, drug interactionsMammalian Target of Rapamycin (mTOR) Inhibitors Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS – Head and Neck Angioedema ).
Trandolapril label, warningsWhere there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, emergency therapy, including but not limited to subcutaneous epinephrine solution 1:1,000 (0.3 to 0.5 mL) should be promptly administered. (See PRECAUTIONS - Information for Patients and ADVERSE REACTIONS .) Patients receiving coadministration of an ACE inhibitor with an mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) or a neprilysin inhibitor (e.g., sacubitril) may be at increased risk for angioedema.
Source: FDA drug label (Trandolapril), Lupin Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8143a6cf-dadc-4ef7-a8db-d16d7150ad34), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Trandolapril | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | High blood pressure |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | $0.157 per tablet 1 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once